Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2017

View Archived Issues

DUSP1 identified as a therapeutic target for pulmonary fibrotic diseases

Ionis Pharmaceuticals' Spinraza approved in E.U. for spinal muscular atrophy

Eleven Biotherapeutics cleared to continue phase III study of Vicinium

Achaogen begins clinical development program of C-Scape

Novel missense mutation in PLEC gene tied to atrial fibrillation

Genentech files regulatory submissions to begin phase I studies of BL-8040 plus atezolizumab

Inovio Pharmaceuticals enters immuno-oncology collaboration with Genentech

Targeting CD98 shrinks malignant mesothelioma tumors in vivo

Orexo receives milestone payment triggered by OX-CLI phase I initiation

The University of Florida and Torrey Pines Institute patent alpha-enolase inhibitors

The University of Rochester presents bortezomib conjugates

Reata reports data from part 1 of phase II MOXIe trial of omaveloxolone in Friedreich's ataxia

Incyte identifies PI3Kgamma inhibitors

Voyager Therapeutics selects Huntington's disease clinical candidate

Mirati Therapeutics divulges LSD1 inhibitors

Biomarin Pharmaceutical wins E.U. approval of Brineura for CLN2

Thetis Pharmaceuticals discloses amino acid salts of saturated fatty acids

Deciphera closes series C financing to support development of oncology products

Vaxon Biotech reports results from phase IIb study of VX-001 cancer vaccine

Novel pyrazolopyridine KDU-731 a candidate for treating cryptosporidiosis

Ligand Pharmaceuticals, Surface Oncology enter OmniAb license agreement

U.S. and E.U. submissions made for dolutegravir/rilpivirine single-tablet regimen for HIV-1

DOCK6 gene found to be involved in ciliopathies

GHIT Fund secures over USD 200 million in commitments for second phase replenishment

FDA approves Roche's companion diagnostic for Zykadia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...